Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
141-160 of 998 trials

Hereditary Angioedema: OCTA-C1-INH Treatment Study

We are studying a new intravenous treatment for people with hereditary angioedema to see if it effectively relieves symptoms during acute attacks. The trial includes adolescents and adults, and also looks at safety and quality of life.

Hereditary Angioedema1-2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteAllergologyHematology

Rare Ovarian Cancer: Abemaciclib and Letrozole Study

We are investigating the effects of a new treatment combining abemaciclib and letrozole for women with estrogen receptor positive rare ovarian cancer. The study aims to understand how well this treatment works and its impact on quality of life.

Adult-type Granulosa Cell TumorLow-Grade Serous Ovarian Cancer>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Advanced Non-Small Cell Lung Cancer: Zipalertinib with Chemotherapy

We are studying whether adding zipalertinib to standard chemotherapy helps patients with advanced non-small cell lung cancer who have a specific genetic mutation. This trial compares the effects of the combination treatment to chemotherapy alone.

Non-Small Cell Lung Cancer6-12 monthsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyPulmonology

Cardiogenic Shock: Early Empagliflozin Treatment

We are studying if starting empagliflozin early helps patients with cardiogenic shock improve their heart function and reduce hospital visits. This trial compares the new treatment with standard care to see which is more effective.

Cardiogenic Shock3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Atopic Dermatitis in Children: Tralokinumab Treatment

We are studying whether a new treatment with tralokinumab and topical steroids helps children aged 2 to under 12 and infants aged 6 months to under 2 manage moderate-to-severe atopic dermatitis better than a placebo. The trial also looks at how this treatment affects daily life and skin health.

Atopic Dermatitis1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Efepoetin Alfa for Anemia in Chronic Kidney Disease on Dialysis

We are studying whether efepoetin alfa can effectively manage anemia in patients with chronic kidney disease on dialysis, compared to another treatment. This trial will also assess safety and quality of life for participants.

Anemia of Chronic Disease1-2 yearsConfirmation phase (III)>20 visitsNo PlaceboInvestigational MedicinesPartially RemoteHematologyNephrology

Breast Cancer-Related Lymphedema: Topical Tacrolimus Study

We are investigating whether a topical ointment can reduce swelling in patients with breast cancer-related lymphedema. This study compares the ointment to a placebo to see if it improves symptoms and quality of life.

Lymphedema1-2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteInternal MedicineOncology

Hidradenitis Suppurativa: Upadacitinib Study

We are testing Upadacitinib in adults and adolescents with moderate to severe Hidradenitis Suppurativa who haven't responded to other treatments. The goal is to see if it is more effective and safe than a placebo.

Hidradenitis Suppurativa>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteDermatology

Advanced Cholangiocarcinoma: Futibatinib Study

We are studying the effects of futibatinib in patients with advanced cholangiocarcinoma with FGFR2 fusions or rearrangements. The goal is to see if it helps improve their condition and to understand its safety.

Cholangiocarcinoma6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Chronic Cutaneous Lupus Erythematosus: Anifrolumab Study

We are investigating whether anifrolumab can improve skin symptoms in adults with chronic cutaneous lupus erythematosus who haven't responded to other treatments. The study will compare its effects to a placebo over 24 weeks.

Cutaneous Lupus Erythematosus1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteDermatologyRheumatology

Fibrotic Interstitial Lung Disease: Morphine for Breathlessness

We are studying whether slow-release morphine can help reduce breathlessness and cough in patients with fibrotic interstitial lung disease. The goal is to see if it improves their overall quality of life.

Fibrotic Interstitial Lung Disease≤3 monthsMonitoring phase (IV)≤5 visitsStandard MedicinesCost ReimbursementPartially RemotePulmonology

Dementia Care: Benefits of Amyloid PET Imaging

We are exploring how amyloid PET imaging may improve care for people with dementia compared to standard diagnostic methods. This study aims to show its impact on important health outcomes.

Dementia>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteNeurologyPsychiatry

Parkinson's Disease: Safinamide vs. Rasagiline for Fatigue

We are studying whether Safinamide or Rasagiline can help reduce fatigue in people with Parkinson's Disease already on stable treatment. The trial will also monitor safety and side effects over six months.

Fatigue in Parkinson's Disease3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteNeurology

Relatlimab and Nivolumab for Young Lymphoma Patients

We are studying a combination of two medications for children and young adults with recurrent or hard-to-treat Hodgkin and Non-Hodgkin lymphoma. The goal is to understand their safety and how well they may work.

Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma3-6 monthsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncologyPediatrics

Elderly Surgery: Comparing Anesthesia Methods

We are studying how desflurane, sevoflurane, and propofol affect the risk of delirium and cognitive function in elderly patients after major abdominal surgery. This research aims to improve recovery outcomes for older adults undergoing surgery.

Postoperative Delirium>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesPartially Remote

Tranexamic Acid for Preventing Bleeding in Tooth Extractions

We are studying whether Tranexamic Acid Oral Solution can help reduce bleeding in patients taking blood thinners during tooth extractions. This trial aims to compare its effects with a placebo.

Bleeding from TeethConfirmation phase (III)Investigational MedicinesPartially RemoteGynecology and ObstetricsHematologyOtolaryngology

Heart Failure and Obesity: Weight Loss with Semaglutide

We are investigating whether weight loss using semaglutide is more effective than a calorie-restricted diet in improving physical performance for patients with heart failure and obesity. The study also looks at quality of life and heart health impacts from both weight loss methods.

Heart Failure with Reduced Ejection FractionObesity1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesPartially RemoteCardiologyDiabetologyEndocrinology

Post-Menopausal Osteoporosis: BP16 vs. EU-Prolia

We are comparing a new treatment, BP16, to EU-Prolia for women with post-menopausal osteoporosis. The study looks at how well each treatment improves bone health and their safety.

Post-Menopausal Osteoporosis1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteEndocrinologyRheumatology

Gastroparesis: Tradipitant Safety Study

We are evaluating the safety of a new medication, tradipitant, for patients with gastroparesis. The study also looks at how well it may help reduce symptoms and improve quality of life.

Gastroparesis3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteEndocrinologyGastroenterology

Major Depressive Disorder: Lumateperone Study

We are testing lumateperone as an additional treatment for people with major depressive disorder who aren't responding well to their current antidepressants. The study will help us understand its effectiveness and safety.

Major Depressive Disorder≤3 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry